ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
- Anders, Hans-Joachim
- Rovin, Brad
- Jayne, David
- Brunetta, Paul
- Coppo, Rosanna
- Davidson, Anne
- Devarapu, Satish Kumar
- de Zeeuw, Dick
- Duffield, Jeremy
- Eulberg, Dirk
- Fierro, Alberto
- Floege, Jürgen
- Frese, Steffen
- Guillevin, Loïc
- Holdsworth, Stephen
- Hughes, Jeremy
- Kettritz, Ralph
- Kluger, Malte
- Krebs, Christian
- Lapteva, Larissa
- Levin, Adeera
- Li, Jinhua
- Lightstone, Liz
- Mack, Matthias
- Mansouri, Ladan
- McAdoo, Stephen
- McKinney, Eoin
- Panzer, Ulf
- Parikh, Samir
- Pusey, Charles
- Putterman, Chaim
- Rabelink, Ton
- Radbruch, Andreas
- Rees, Andrew
- Reilly, Mary
- Reinders, Marlies
- Remuzzi, Giuseppe
- Ruggenenti, Piero
- Sacks, Steven
- Schall, Thomas J
- Meyer-Schwesinger, Catherine
- Sharma, Kumar
- Suzuki, Yusuke
- Tomas, Nicola M.
- Zhao, Ming-Hui
DOIAbstract
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulato...